

Zhaohui Jin

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1362487/publications.pdf>

Version: 2024-02-01

49
papers

2,115
citations

394421

19
h-index

243625

44
g-index

49
all docs

49
docs citations

49
times ranked

2859
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor Mutational Burden as a Predictive Biomarker in Solid Tumors. <i>Cancer Discovery</i> , 2020, 10, 1808-1825.	9.4	388
2	G protein-coupled receptor 56 and collagen III, a receptor-ligand pair, regulates cortical development and lamination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2011, 108, 12925-12930.	7.1	235
3	GPR56 Regulates Pial Basement Membrane Integrity and Cortical Lamination. <i>Journal of Neuroscience</i> , 2008, 28, 5817-5826.	3.6	209
4	A Functional Role for Nicotine in Bcl2 Phosphorylation and Suppression of Apoptosis. <i>Journal of Biological Chemistry</i> , 2003, 278, 1886-1891.	3.4	136
5	Nicotine Induces Multi-site Phosphorylation of Bad in Association with Suppression of Apoptosis. <i>Journal of Biological Chemistry</i> , 2004, 279, 23837-23844.	3.4	117
6	Tobacco-specific Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone Promotes Functional Cooperation of Bcl2 and c-Myc through Phosphorylation in Regulating Cell Survival and Proliferation. <i>Journal of Biological Chemistry</i> , 2004, 279, 40209-40219.	3.4	110
7	Disease-associated mutations affect GPR56 protein trafficking and cell surface expression. <i>Human Molecular Genetics</i> , 2007, 16, 1972-1985.	2.9	109
8	GPR56-Regulated Granule Cell Adhesion Is Essential for Rostral Cerebellar Development. <i>Journal of Neuroscience</i> , 2009, 29, 7439-7449.	3.6	85
9	The promise of PD-1 inhibitors in gastro-esophageal cancers: microsatellite instability vs. PD-L1. <i>Journal of Gastrointestinal Oncology</i> , 2016, 7, 771-788.	1.4	84
10	Bcl2 Suppresses DNA Repair by Enhancing c-Myc Transcriptional Activity. <i>Journal of Biological Chemistry</i> , 2006, 281, 14446-14456.	3.4	62
11	Mismatch Repair-Deficient Colorectal Cancer: Building on Checkpoint Blockade. <i>Journal of Clinical Oncology</i> , 2022, 40, 2735-2750.	1.6	62
12	Disease-Associated Mutations Prevent GPR56-Collagen III Interaction. <i>PLoS ONE</i> , 2012, 7, e29818.	2.5	50
13	Survival Function of Protein Kinase C δ as a Novel Nitrosamine 4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanone-activated Bad Kinase. <i>Journal of Biological Chemistry</i> , 2005, 280, 16045-16052.	3.4	47
14	Prognostic factors and benefits of adjuvant therapy after pancreatoduodenectomy for ampullary adenocarcinoma: Mayo Clinic experience. <i>European Journal of Surgical Oncology</i> , 2018, 44, 677-683.	1.0	44
15	Outcome of Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 1083-1091.	3.7	39
16	Impact of Metastasectomy in the Multimodality Approach for BRAF V600E Metastatic Colorectal Cancer: The Mayo Clinic Experience. <i>Oncologist</i> , 2018, 23, 128-134.	3.7	34
17	Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancers, 2021, 13, 300.	3.7	32
18	Clinicopathological and Molecular Characteristics of Early-Onset Stage III Colon Adenocarcinoma: An Analysis of the ACCENT Database. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1693-1704.	6.3	25

#	ARTICLE	IF	CITATIONS
19	A Novel GPR56 Mutation Causes Bilateral Frontoparietal Polymicrogyria. <i>Pediatric Neurology</i> , 2011, 45, 49-53.	2.1	23
20	Identifying and Meeting the Needs of Adolescents and Young Adults with Cancer. <i>Current Oncology Reports</i> , 2021, 23, 17.	4.0	21
21	Local excision for patients with stage I anal canal squamous cell carcinoma can be curative. <i>Journal of Gastrointestinal Oncology</i> , 2019, 10, 171-178.	1.4	20
22	Chapter 1 GPR56 and Its Related Diseases. <i>Progress in Molecular Biology and Translational Science</i> , 2009, 89, 1-13.	1.7	19
23	<p>Evaluating the Safety and Efficacy of Nivolumab in Patients with Advanced Hepatocellular Carcinoma: Evidence to Date</p>. <i>OncoTargets and Therapy</i> , 2019, Volume 12, 10335-10342.	2.0	19
24	A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional Experience. <i>Oncologist</i> , 2018, 23, 679-685.	3.7	16
25	Novel Prognostic Factors in Resected Small Bowel Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2019, 18, 218-225.	2.3	13
26	Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer. <i>Journal of the National Cancer Institute</i> , 2021, 113, 1705-1713.	6.3	12
27	Survival and prognostic factors in patients with rectal squamous cell carcinoma. <i>European Journal of Surgical Oncology</i> , 2020, 46, 1111-1117.	1.0	12
28	First-Line Targeted Therapy for Hepatocellular Carcinoma: Role of Atezolizumab/Bevacizumab Combination. <i>Biomedicines</i> , 2022, 10, 1304.	3.2	9
29	Multicenter phase Ib trial in the U.S. of salvage CT041 CLDN18.2-specific chimeric antigen receptor T-cell therapy for patients with advanced gastric and pancreatic adenocarcinoma.. <i>Journal of Clinical Oncology</i> , 2022, 40, 2538-2538.	1.6	9
30	Systemic treatment for hepatocellular carcinoma. <i>Chronic Diseases and Translational Medicine</i> , 2018, 4, 148-155.	1.2	8
31	Research on Anal Squamous Cell Carcinoma: Systemic Therapy Strategies for Anal Cancer. <i>Cancers</i> , 2021, 13, 2180.	3.7	8
32	Antiangiogenic Therapy in Gastroesophageal Cancer. <i>Hematology/Oncology Clinics of North America</i> , 2017, 31, 499-510.	2.2	7
33	Optimizing Biologic Sequencing in Metastatic Colorectal Cancer: First Line and Beyond. <i>Current Oncology</i> , 2019, 26, 33-42.	2.2	7
34	Management of Non-Colorectal Digestive Cancers with Microsatellite Instability. <i>Cancers</i> , 2021, 13, 651.	3.7	7
35	Advances in the therapy of BRAF^{V600E} metastatic colorectal cancer. <i>Expert Review of Anticancer Therapy</i> , 2019, 19, 823-829.	2.4	5
36	Solid Pseudopapillary Neoplasms of the Pancreas. <i>Pancreas</i> , 2019, 48, e21-e22.	1.1	5

#	ARTICLE	IF	CITATIONS
37	Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer. <i>Pancreatology</i> , 2021, 21, 379-383.	1.1	5
38	Reevaluating Disease-Free Survival as an Endpoint vs Overall Survival in Stage III Adjuvant Colon Cancer Trials. <i>Journal of the National Cancer Institute</i> , 2022, 114, 60-67.	6.3	5
39	Association of magnitude and consistency of PD-L1 expression and other variables associated with benefit from immune checkpoint inhibition (ICI): Systematic review and meta-analysis of 14 phase 3 trials in advanced gastroesophageal cancer (GEC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 344-344.	1.6	4
40	Tumor Mutational Burden Is a Potential Predictive Biomarker for Response to Immune Checkpoint Inhibitors in Patients With Advanced Biliary Tract Cancer. <i>JCO Precision Oncology</i> , 2022, , .	3.0	4
41	Rectal cancer with synchronous inguinal lymph node metastasis without distant metastasis. A call for further oncological evaluation. <i>European Journal of Surgical Oncology</i> , 2022, 48, 1100-1103.	1.0	3
42	FGFR Inhibitor Toxicity and Efficacy in Cholangiocarcinoma: Multicenter Single-Institution Cohort Experience. <i>JCO Precision Oncology</i> , 2021, 5, 1228-1240.	3.0	2
43	Falls: descriptive rates and circumstances in age-unspecified patients with locally advanced esophageal cancer. <i>Supportive Care in Cancer</i> , 2021, 29, 733-739.	2.2	2
44	Identification of Adenosquamous Carcinoma as a Rare Aggressive HER2-negative Subgroup of Esophageal/Gastroesophageal Junction Adenocarcinoma. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2019, 42, 190-195.	1.3	1
45	Nanoliposomal irinotecan-based chemotherapy after regular irinotecan-based chemotherapy in patients with pancreas cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, 402-402.	1.6	1
46	Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3597-3597.	1.6	0
47	Prognostic value of tumor deposits in stage III colon cancer patients, a post-hoc analysis of CALGB/SWOG 80702 phase III study.. <i>Journal of Clinical Oncology</i> , 2021, 39, 10-10.	1.6	0
48	REVERCEII (ACCRU-GI-1809): A randomized phase II study of regorafenib followed by anti-EGFR monoclonal antibody therapy versus the reverse sequencing for metastatic colorectal cancer patients previously treated with fluoropyrimidine, oxaliplatin and irinotecan.. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS213-TPS213.	1.6	0
49	A glimpse into the future of esophageal carcinoma in the United States: Predicting the future incidence based on the current epidemiological data.. <i>Journal of Clinical Oncology</i> , 2022, 40, 248-248.	1.6	0